These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22246718)

  • 1. Preoperative hydronephrosis: independent predictor for changes in renal function following nephroureterectomy.
    Hoshino K; Kikuchi E; Tanaka N; Akita H; Ito Y; Miyajima A; Jinzaki M; Oya M
    Jpn J Clin Oncol; 2012 Mar; 42(3):202-7. PubMed ID: 22246718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
    Dash A; Galsky MD; Vickers AJ; Serio AM; Koppie TM; Dalbagni G; Bochner BH
    Cancer; 2006 Aug; 107(3):506-13. PubMed ID: 16773629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinoma.
    Rodríguez Faba O; Palou J; Breda A; Maroto P; Fernández Gómez JM; Wong A; Villavicencio H
    Urol Int; 2014; 92(2):169-73. PubMed ID: 24280761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy.
    Xylinas E; Rink M; Margulis V; Clozel T; Lee RK; Comploj E; Novara G; Raman JD; Lotan Y; Weizer A; Roupret M; Pycha A; Scherr DS; Seitz C; Ficarra V; Trinh QD; Karakiewicz PI; Montorsi F; Zerbib M; Shariat SF;
    BJU Int; 2013 Aug; 112(4):453-61. PubMed ID: 23464979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of renal function after nephroureterectomy in patients with upper tract urothelial carcinoma.
    Hashimoto T; Ohno Y; Nakashima J; Gondo T; Nakagami Y; Namiki K; Horiguchi Y; Yoshioka K; Ohori M; Tachibana M
    Jpn J Clin Oncol; 2015 Nov; 45(11):1064-8. PubMed ID: 26355160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer.
    Tsao CK; Moshier E; Seng SM; Godbold J; Grossman S; Winston J; Oh WK; Galsky MD
    Clin Genitourin Cancer; 2012 Mar; 10(1):15-20. PubMed ID: 22130294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma.
    Messer JC; Terrell JD; Herman MP; Ng CK; Scherr DS; Scoll B; Boorjian SA; Uzzo RG; Wille M; Eggener SE; Lucas SM; Lotan Y; Shariat SF; Raman JD
    Urol Oncol; 2013 Aug; 31(6):904-8. PubMed ID: 21906967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N; Arima K; Sugimura Y
    Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients.
    Thompson RH; Boorjian SA; Kim SP; Cheville JC; Thapa P; Tarrel R; Dronca R; Costello B; Frank I
    BJU Int; 2014 May; 113(5b):E17-21. PubMed ID: 24006893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract.
    Cho KS; Joung JY; Seo HK; Cho IC; Chung HS; Chung J; Lee KH
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):769-74. PubMed ID: 20532510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration.
    Hellenthal NJ; Shariat SF; Margulis V; Karakiewicz PI; Roscigno M; Bolenz C; Remzi M; Weizer A; Zigeuner R; Bensalah K; Ng CK; Raman JD; Kikuchi E; Montorsi F; Oya M; Wood CG; Fernandez M; Evans CP; Koppie TM
    J Urol; 2009 Sep; 182(3):900-6. PubMed ID: 19616245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
    Raj GV; Karavadia S; Schlomer B; Arriaga Y; Lotan Y; Sagalowsky A; Frenkel E
    Cancer; 2011 Jan; 117(2):276-82. PubMed ID: 20830767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma.
    Kaag M; Trost L; Thompson RH; Favaretto R; Elliott V; Shariat SF; Maschino A; Vertosick E; Raman JD; Dalbagni G
    BJU Int; 2014 Nov; 114(5):674-9. PubMed ID: 24314050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series.
    Bartsch GC; Kuefer R; Gschwend JE; de Petriconi R; Hautmann RE; Volkmer BG
    Eur Urol; 2007 Mar; 51(3):690-7; discussion 697-8. PubMed ID: 16904815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of contralateral kidney volume on renal function after radical nephroureterectomy: Implications for eligibility for neoadjuvant chemotherapy for upper tract urothelial cancer.
    Song W; Sung HH; Han DH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
    Urol Oncol; 2017 Mar; 35(3):114.e1-114.e7. PubMed ID: 27908680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract.
    Ku JH; Choi WS; Kwak C; Kim HH
    Urol Oncol; 2011; 29(4):383-7. PubMed ID: 19556154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of different methods of estimating renal function on determining eligibility for cisplatin (CDDP)-based chemotherapy in patients with invasive urothelial carcinoma].
    Goto T; Yoshimura K; Matsui Y; Shimizu Y; Inoue T; Okubo K; Kamba T; Nishiyama H; Ogawa O
    Hinyokika Kiyo; 2011 Dec; 57(12):671-6. PubMed ID: 22240299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
    Raj GV; Iasonos A; Herr H; Donat SM
    J Clin Oncol; 2006 Jul; 24(19):3095-100. PubMed ID: 16809735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.